CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price fell 2.1% during mid-day trading on Tuesday . The stock traded as low as $0.2230 and last traded at $0.2304. Approximately 2,577,568 shares traded hands during mid-day trading, an increase of 39% from the average session volume of 1,859,706 shares. The stock had previously closed at $0.2354.
CytoDyn Stock Down 2.1%
The firm’s 50 day moving average price is $0.30 and its two-hundred day moving average price is $0.28. The firm has a market capitalization of $317.31 million, a PE ratio of -7.68 and a beta of 1.16.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Read More
- Five stocks we like better than CytoDyn
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
